eSupervisor Detail

About me

My research interests focus on preclinical pharmacology, toxicology, and neuropharmacology, particularly in vivo models for drug development. I am interested in neurodegenerative disorders, PK/TK studies, and safety evaluation of therapeutics. I also aim to explore biologics, biosimilars, and impurity profiling, integrating molecular techniques to understand drug action and support the development of safe and effective treatments.

Interests: My research interests lie at the intersection of preclinical pharmacology, toxicology, and neuropharmacology, with a strong focus on understanding disease mechanisms and evaluating the safety and efficacy of therapeutic agents. I am particularly interested in in vivo experimental models, where I can integrate pharmacological principles with translational research approaches to contribute to drug discovery and development. During my academic and professional journey, I have developed a keen interest in neurodegenerative and neurological disorders. My Master’s research focused on exploring the neuroprotective potential of agmatine in a 3-nitropropionic acid-induced model of Huntington’s disease in rats. This work enhanced my understanding of disease pathology, behavioral assessments, and molecular mechanisms such as neuroinflammation and gene expression. It also strengthened my interest in identifying novel therapeutic targets and strategies to mitigate neurodegeneration. Alongside neuropharmacology, I have a strong interest in general toxicology and safety evaluation of new chemical entities. In my current role as a Junior Research Officer, I have gained hands-on experience in repeated-dose toxicity, developmental and reproductive toxicology, and safety pharmacology studies under GLP, OECD, and ICH guidelines. I am particularly interested in understanding dose-response relationships, target organ toxicity, and the interpretation of toxicological endpoints to support safe and effective drug development. I am also highly interested in pharmacokinetics (PK) and toxicokinetics (TK), especially in understanding drug absorption, distribution, metabolism, and excretion, and how these factors influence therapeutic outcomes. I believe integrating PK/TK data with pharmacodynamic responses is essential for optimizing dosing strategies and minimizing adverse effects. In addition, I have developed a growing interest in biologics and biosimilars, particularly in their preclinical safety assessment, immunogenicity, and comparability studies. I am also interested in the role of impurities and degradation products in pharmaceuticals, and how they impact drug safety, efficacy, and regulatory compliance. Understanding impurity profiling and its toxicological implications is an important area that I aim to explore further. Another important area of my interest is the development and refinement of experimental animal models. I have experience working with models such as the Middle Cerebral Artery Occlusion (MCAO) model for ischemic stroke, and I am motivated to explore models that closely replicate human disease conditions. I am also interested in improving the translational relevance and ethical aspects of preclinical research. Furthermore, I am interested in integrating pharmacological studies with molecular and biochemical techniques such as ELISA, RT-PCR, and immunohistochemistry to better understand cellular and molecular responses to treatments. This combined approach allows for a deeper and more comprehensive evaluation of drug action and toxicity. Overall, my goal is to contribute to the development of safe, effective, and high-quality therapeutics by applying strong experimental design, advanced in vivo techniques, and a thorough understanding of regulatory standards. I am eager to expand my knowledge, collaborate across disciplines, and contribute meaningfully to research in pharmacology, toxicology, and emerging areas such as biologics and biosimilars.